13,969 Shares in Henry Schein, Inc. $HSIC Acquired by Redwood Investment Management LLC

Redwood Investment Management LLC acquired a new stake in Henry Schein, Inc. (NASDAQ:HSIC) in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 13,969 shares of the company’s stock, valued at approximately $1,167,000.

Other hedge funds have also recently added to or reduced their stakes in the company. CYBER HORNET ETFs LLC acquired a new position in shares of Henry Schein during the second quarter worth $25,000. MUFG Securities EMEA plc bought a new stake in Henry Schein during the 2nd quarter worth $27,000. Federated Hermes Inc. acquired a new position in Henry Schein in the 4th quarter worth about $32,000. Los Angeles Capital Management LLC bought a new position in Henry Schein in the fourth quarter valued at about $37,000. Finally, Trust Co. of Vermont acquired a new stake in shares of Henry Schein during the second quarter valued at about $42,000. Institutional investors and hedge funds own 96.62% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently weighed in on the company. Mizuho reduced their price target on Henry Schein from $88.00 to $82.00 and set a “neutral” rating on the stock in a report on Wednesday, May 6th. Citigroup reiterated a “buy” rating and issued a $112.00 price objective (up from $100.00) on shares of Henry Schein in a report on Wednesday, August 5th. Barrington Research set a $104.00 target price on shares of Henry Schein in a research report on Wednesday, August 5th. Barclays reissued an “overweight” rating and set a $100.00 target price (up from $86.00) on shares of Henry Schein in a report on Thursday, August 6th. Finally, BMO Capital Markets started coverage on shares of Henry Schein in a research report on Wednesday, July 8th. They issued a “market perform” rating and a $85.00 price target for the company. Nine research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Henry Schein presently has a consensus rating of “Moderate Buy” and an average price target of $92.93.

Henry Schein News Roundup

Here are the key news stories impacting Henry Schein this week:

• Positive Sentiment: Long-term earnings estimates improved. Zacks Research raised its FY2026 EPS forecast to $5.32 from $5.30, FY2027 EPS to $5.82 from $5.81, and FY2028 EPS to $6.32 from $6.29. The firm also lifted its Q1 2027 estimate to $1.38 from $1.37 and Q2 2028 to $1.56 from $1.46. These revisions suggest analysts see continued earnings growth for Henry Schein over the next several years.
• Positive Sentiment: Valuation remains a focus for investors. A Zacks comparison examines whether Henry Schein or Straumann Holding AG offers the better value among medical and dental-supply companies. Favorable value characteristics could support HSIC’s appeal, although the article does not represent a new company-specific fundamental announcement. HSIC vs. SAUHY: Which Stock Is the Better Value Option?
• Neutral Sentiment: Short-interest data showed no meaningful signal. The report lists short interest at zero shares and a zero-day days-to-cover ratio, while also showing an undefined percentage change. Because the figures appear inconsistent or incomplete, they are unlikely to provide a reliable explanation for the stock’s move.
• Negative Sentiment: Several near-term EPS forecasts were trimmed. Zacks lowered its Q3 2026 EPS estimate to $1.33 from $1.38, Q4 2026 to $1.40 from $1.42, Q1 2028 to $1.57 from $1.64, and Q2 2027 to $1.39 from $1.40. The near-term reductions introduce some caution, although the FY2026 estimate remains close to the $5.35 consensus forecast.

Henry Schein Price Performance

HSIC stock opened at $90.38 on Thursday. The firm has a market cap of $10.07 billion, a price-to-earnings ratio of 26.35, a PEG ratio of 1.71 and a beta of 0.80. The company has a quick ratio of 0.73, a current ratio of 1.32 and a debt-to-equity ratio of 0.60. Henry Schein, Inc. has a 12-month low of $61.94 and a 12-month high of $92.18. The company’s fifty day simple moving average is $86.28 and its 200 day simple moving average is $79.86.

Henry Schein (NASDAQ:HSIC) last issued its quarterly earnings results on Tuesday, August 4th. The company reported $1.27 earnings per share for the quarter, topping analysts’ consensus estimates of $1.24 by $0.03. Henry Schein had a return on equity of 15.97% and a net margin of 2.96%.The firm had revenue of $3.46 billion during the quarter, compared to the consensus estimate of $3.37 billion. During the same period last year, the business posted $1.10 EPS. The business’s revenue was up 6.7% compared to the same quarter last year. Henry Schein has set its FY 2026 guidance at 5.290-5.390 EPS. On average, analysts expect that Henry Schein, Inc. will post 5.36 earnings per share for the current year.

Henry Schein Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.